Collateral for a security interest recorded Oct 1, 2025 (Bank of America, N.A.).
Term ends May 10, 2027 · Low confidence
20-year base term ends May 10, 2027
Held by Alnylam Pharmaceuticals, Inc.
Filed Nov 8, 2017 as application 15/807,275 · Granted Dec 10, 2019
Base term, 20 years from filing
Today
2007
2027
Clock starts
May 10, 2007
May 10, 2007
Term ends
May 10, 2027
May 10, 2027
Granted
Dec 10, 2019
Dec 10, 2019
base term
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 9,822,365, to May 10, 2027. The term already ends on or before that date, so the cap shortened nothing.
1 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
10
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 1 maintenance fees is paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 10, 2007, when application 11/746,864, the earliest non-provisional in its chain, was filed (this one was filed Nov 8, 2017); a parent in its chain could not be resolved (the next row) | May 10, 2027 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,822,365) | resolves to May 10, 2027, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 1 maintenance fees paid | In force | High confidence |
| Further caveats on record | The record names parents not resolved: 14330923, 14330923 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | May 10, 2027 | Low confidence |
This family
| US 7,605,251 | In force May 2027 | May 2027 |
| US 8,222,222 | In force Dec 2027 | Dec 2027 |
| US 8,809,292 | In force May 2027 | May 2027 |
| US 9,260,718 | In force May 2027 | May 2027 |
| US 9,822,365 | In force May 2027 | May 2027 |
| US 10,501,742 | this patent May 2027 | May 2027 |
| Application 16/675,035 | Abandoned not computed | not computed |
| Application 17/186,078 | Abandoned not computed | not computed |
8 of 10 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 9, 2017 Reel 44086, frame 844 | Frank-kamenetsky, Maria; Fitzgerald, Kevin; Akinc, Akin; Kotelianski, Victor E. | Alnylam Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Nov 9, 2017 Reel 44086, frame 858 | Tan, Pamela; Bramlage, Birgit | Alnylam Europe AG | Assignment of Assignor's Interest |
| Nov 9, 2017 Reel 44086, frame 864 | Alnylam Europe AG | Alnylam Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Oct 1, 2025 Reel 72996, frame 337 | Alnylam Pharmaceuticals, Inc.; Sirna Therapeutics, Inc. | Bank Of America, N.a. | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
May 2027
Term ends May 10, 2027. No further fees fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 9,822,365, ends no earlier than this term, so it caps nothing.
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2019 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.